Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults

References

• Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine 2014; 32: 2364-74; PMID:24606865; http://dx.doi.org/10.1016/j.vaccine.2014.02.002
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31: 3585-93; PMID:23688527; http://dx.doi.org/10.1016/j.vaccine.2013.05.010
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31: 3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Flamaing J, Rumke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011; 29: 5195-202; PMID:21619909; http://dx.doi.org/10.1016/j.vaccine.2011.05.031
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31: 297-301; PMID:22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59: 1066-3; PMID:25034421; http://dx.doi.org/10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9; [Epub ahead of print]; PMID:25656600; http://dx.doi.org/10.1016/S1473-3099(14)71081-3
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
   PubMed Web of Science ®Google Scholar
• Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67: 540-5; PMID:22374921; http://dx.doi.org/10.1136/thoraxjnl-2011-201092
   PubMed Web of Science ®Google Scholar
• Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM, Jr. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged >/=50 years with community-acquired pneumonia. J Infect Dis 2013; 208: 1813-20; PMID:24092845; http://dx.doi.org/10.1093/infdis/jit506
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Wunderink RG, Williams D, Zhu Y, Balk R, Fakhran S, Courtney M, Anderson E, Qi C, Hicks L, et al. Distribution of pneumococcal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. Presented at: 9th International Symposium on Pneumococci and Pneumococcal Diseases; March 9–13, 2014; Hyderabad, India.
   Google Scholar
• Payeras A, Villoslada A, Garau M, Salvador MN, Gallegos MC. Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine. Int J Infect Dis 2014; 33: 22-7; PMID:25541296; http://dx.doi.org/10.1016/j.ijid.2014.12.035
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent oneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63: 822-5; PMID:25233284
   PubMed Web of Science ®Google Scholar
• Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R. The immunogenicity of Prevnar 13 in immunocompetent older adults with stable underlying medical conditions is comparable to that in healthy older adults. Presented at: IDWeek; October 17–21, 2012; San Diego, CA.
   Google Scholar
• Schmoele-Thoma B, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Isturiz R, Sundaraiyer V, Gruber WC, Scott DA. The immunogenicity of PCV13 compared with PPSV23 in immunocompetent older adults with stable at-risk conditions. Presented at: IDWeek; October 8–12, 2014; Philadelphia, PA, USA.
   Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO, Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32: 203-7; PMID:23558320; http://dx.doi.org/10.1097/INF.0b013e318275614b
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, Dorleans F, Janoir C, Gutmann L, Levy-Bruhl D. Microbiologists of Epibac, ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012. Vaccine 2015; 33: 359-66; PMID:25448105; http://dx.doi.org/10.1016/j.vaccine.2014.11.011
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, Ronning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013; 31: 6232-8; PMID:24176490; http://dx.doi.org/10.1016/j.vaccine.2013.10.032
   PubMed Web of Science ®Google Scholar